ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Pfizer invests in U.S., eases up in Ireland

by Alex Scott
December 5, 2016 | APPEARED IN VOLUME 94, ISSUE 48

Pfizer is set to invest more than $200 million to build R&D and process development facilities in St. Louis County, Mo. The planned facilities will be used to advance biotherapeutics including vaccines, immuno-oncology therapies, monoclonal antibodies, and biosimilars. Pfizer expects construction to begin in 2017. Meanwhile, Pfizer says it will ease back on expansion plans in Clondalkin, Ireland, following the phase III clinical trial failure of its cholesterol-lowering drug candidate bococizumab, a proprotein convertase subtilisin kexin type-9 inhibitor. The trial found an unanticipated reduction of low-density lipoprotein cholesterol. Pfizer had applied for planning permission to build a 34,000 m2 facility to manufacture the drug. Some media reports state the investment would have been about $425 million. Pfizer would not comment on costs but says some expansion will still take place at the site to accommodate other products.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment